Melbourne, Australia-based Mesoblast Limited announced promising data from a phase 2 trial of the company’s novel stem cell therapy for patients with rheumatoid arthritis (RA), which shows its therapeutic benefits continued 9 months after administration of a single intravenous (IV) dose.
The stem cell infusion of Mesoblast’s allogeneic Mesenchymal Precursor Cells (MPC)-300-IV was administered to 48 RA patients resistant to anti-Tumor Necrosis Factor (TNF) agents. A single IV dose of 2 million MPC/kg of MPC-300-IV was well tolerated and demonstrated a durable improvement in clinical symptoms, physical function, and disease activity relative to placebo over the follow-up period.
Approximately a third of RA patients develop resistance to TNF agents; others patients do not respond to the drugs or experience adverse events when using them. Second-line drugs such as Rituxan are not as effective as the anti-TNF agents and are associated with serious side effects.
The phase 2 study patients had active RA, were on a stable regimen of methotrexate, and had an inadequate prior clinical response to at least 1 anti-TNF agent. Of the 48 patients, 30 (68%) had previously received 1 to 2 biologic agents. Patients were randomized to a single IV infusion of 1 million MPCs/kg, 2 million MPCs/kg, or placebo. Patients were evaluated using the American College of Rheumatology (ACR) 20/50/70 measurement to assess clinical response and improvement in signs and symptoms of RA in terms of 20%, 50%, or 70% improvement from baseline. The study also used the ACR-N scale to assess mean or median magnitude of benefit, assessed health/disability with the HAQ-DI measure for functional status, and applied the DAS28 scale to measure RA disease activity in order to judge improvement.
The safety profile over 39 weeks was comparable among placebo and both MPC treatment groups, with no cell-related serious adverse events. Both MPC doses tested outperformed placebo at week 39 in each of the ACR20/50/70 responses. The 2 million MPCs/kg dose was found to be the most effective over 39 weeks; that dose also achieved the maximal ACR-N score earlier (at 12 weeks) and exhibited a more robust durable effect.
Mesoblast CEO Silviu Itescu said the company’s MPC therapies have demonstrated virtually no toxicity, and had generated no negative immune response. The cells also appear to be targeted, intrinsically moving toward sites of inflammation and embedding in tissue, he said. Receptors on the cells’ surface are activated by every major cytokine that is important in progressive RA, including TNF, interleukin (IL)-1, IL-6, and IL-17. Itescu believes MPC-300-IV has an edge on the biologics inhibiting TNF-alpha or other key targets because it is getting to the heart of the inflammation and disease, not just knocking back the immune system.
Although larger phase 3 studies are needed to validate these results, the data are intriguing in that they suggest what optimized and targeted regenerative medicines could potentially accomplish to address the unmet medical need among anti-TNF—resistant RA patients.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.